EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Combining TIGIT blockade with IL‐15 stimulation is a promising immunotherapy strategy for lung adenocarcinoma

Baohong Luo iD, Yu Sun, Qinru Zhan, Yuting Luo, Yu Chen, Tongze Fu, Tiantian Yang, Lijuan Ren, Zhongpeng Xie, Xiaohua Situ, Bixia Liu, Kejing Tang und 1 weitere

Clinical and Translational Medicine · 2024

DOI: 10.1002/ctm2.1553 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Medicine, 2024. Verfasst von Baohong Luo und 12 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Diagnosis and Gene Test Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Lung Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Guangdong/Guangzhou Science and Technology Planning Program, China Postdoctoral Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

T‐cell immunoglobulin and immunoreceptor tyrosine‐based inhibitory motif domain (TIGIT) is an immune checkpoint molecule that suppresses CD8 + T‐cell function in cancer. However, the expression profile and functional significance of TIGIT in the immune microenvironment of lung adenocarcinoma (LUAD) remain elusive. Interleukin (IL)‐15 has emerged as a promising candidate for enhancing CD8 + T‐cell mediated tumour eradication. Exploring therapeutic strategies that combine IL‐15 with TIGIT blockade in LUAD is warranted.

Methods

We investigated the regulatory network involving coinhibitory TIGIT and CD96, as well as costimulatory CD226 in LUAD using clinical samples. The potential role of TIGIT in regulating the pathogenesis of LUAD was addressed through a murine model with transplanted tumours constructed in Tigit −/− mice. The therapeutic strategy that combines TIGIT blockade with IL‐15 stimulation was verified using a transplanted tumour murine model and a patient‐derived organoid (PDO) model.

Results

The frequency of TIGIT + CD8 + T cells was significantly increased in LUAD. Increased TIGIT expression indicated poorer prognosis in LUAD patients. Furthermore, the effector function of TIGIT + CD8 + tumour‐infiltrating lymphocytes (TILs) was impaired in LUAD patients and TIGIT inhibited antitumour immune response of CD8 + TILs in tumour‐bearing mice. Mechanistically, IL‐15 enhanced the effector function of CD8 + TILs but stimulated the expression of TIGIT on CD8 + TILs concomitantly. The application of IL‐15 combined with TIGIT blockade showed additive effects in enhancing the cytotoxicity of CD8 + TILs and thus further increased the antitumour immune response in LUAD.

Conclusions

Our findings identified TIGIT as a promising therapeutic target for LUAD. LUAD could benefit more from the combined therapy of IL‐15 stimulation and TIGIT blockade.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adenocarcinoma of LungLung NeoplasmsAnimalsHumansMiceCD8-Positive T-LymphocytesDisease Models, AnimalImmunotherapyInterleukin-15Receptors, ImmunologicTumor Microenvironment

Stichwörter der Autor:innen

IL-15TIGITimmunotherapylung adenocarcinoma

Substanzen

Interleukin-15Receptors, ImmunologicTIGIT protein, human

Autor:innen und Institutionen

  • Molecular Diagnosis and Gene Test Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
  • Department of Pathology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
  • Department of Pathology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China.
  • Division of Pulmonary and Critical Care Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.

ORCID-Profile: Baohong Luo, Zunfu Ke

Förderung

  • National Natural Science Foundation of China
  • Guangdong/Guangzhou Science and Technology Planning Program
  • China Postdoctoral Science Foundation

Zitieren

APA

Luo, B., Sun, Y., Zhan, Q., Luo, Y., Chen, Y., Fu, T., Yang, T., Ren, L., Xie, Z., Situ, X., Liu, B., Tang, K., & Ke, Z. (2024). Combining TIGIT blockade with IL‐15 stimulation is a promising immunotherapy strategy for lung adenocarcinoma. Clinical and Translational Medicine. https://doi.org/10.1002/ctm2.1553

Vancouver

Luo B, Sun Y, Zhan Q, Luo Y, Chen Y, Fu T, et al. Combining TIGIT blockade with IL‐15 stimulation is a promising immunotherapy strategy for lung adenocarcinoma. Clinical and Translational Medicine. 2024. doi:10.1002/ctm2.1553

BibTeX
@article{Luo2024,
  author = {Luo, Baohong and Sun, Yu and Zhan, Qinru and Luo, Yuting and Chen, Yu and Fu, Tongze and Yang, Tiantian and Ren, Lijuan and Xie, Zhongpeng and Situ, Xiaohua and Liu, Bixia and Tang, Kejing and Ke, Zunfu},
  title = {Combining TIGIT blockade with IL‐15 stimulation is a promising immunotherapy strategy for lung adenocarcinoma},
  journal = {Clinical and Translational Medicine},
  year = {2024},
  doi = {10.1002/ctm2.1553}
}
Kostenlos starten →